A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With PH Due to COPD



Status:Recruiting
Conditions:Chronic Obstructive Pulmonary Disease, High Blood Pressure (Hypertension), High Blood Pressure (Hypertension), Pulmonary
Therapuetic Areas:Cardiology / Vascular Diseases, Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - Any
Updated:3/16/2019
Start Date:June 27, 2018
End Date:September 2020
Contact:Prakash Sista, Ph.D.
Email:304perfectstudy@lungbiotechnology.com
Phone:240-821-1661

Use our guide to learn which trials are right for you!

A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

This is a multicenter, randomized, double-blind, placebo-controlled, 30-week, adaptive
cross-over study, with a Treatment Period of approximately 26 weeks under the Original Design
or, if applicable, a 17-week parallel study, with a Treatment Period of approximately 14
weeks under the Contingent Design.


Inclusion Criteria:

1. Subject voluntarily gives informed consent to participate in the study.

2. Males and females aged 18 years or older at the time of informed consent.

1. Females of childbearing potential must not be pregnant or lactating, and will
either abstain from intercourse, or use two medically acceptable,
highly-effective forms of contraception for the duration of study.

2. Males with a partner of childbearing potential must agree to use a condom for the
duration of treatment and for at least 48 hours after discontinuing study drug.

3. The subject has a clinical diagnosis of PH-COPD (WHO Group 3) using the Global
Initiative for Chronic Obstructive Lung Disease (GOLD) diagnostic criteria and
post-bronchodilator spirometry.

4. The subject has a resting peripheral capillary oxygen saturation (SpO2) ≥90%, with or
without supplemental oxygen, not to exceed 10 L/min.

5. The subject's baseline 6MWD must be at least 100 meters.

6. Subjects are required to have a right heart catheterization (RHC) including a
vasodilator test, with and without oxygen challenge, prior to randomization with the
following documented parameters:

1. Pulmonary vascular resistance (PVR) >4 Wood Units (WU) and

2. A pulmonary artery wedge pressure (PAWP) or left ventricular end-diastolic
pressure (LVEDP) of ≤15 mmHg

3. A pulmonary arterial pressure mean (PAPm) of ≥30 mmHg

7. Subjects on a chronic COPD medication therapy must be on a stable and optimized dose
for ≥30 days prior to Screening Visit.

8. Subjects on medications for conditions unrelated to COPD must be on a stable and
optimized dose for ≥30 days prior to start of Screening Visit 1 and remain on stable
doses throughout the Screening Period. Exceptions are anticoagulants and diuretics.

9. In the opinion of the Investigator, the subject is able to communicate effectively
with study personnel, and is considered reliable, willing and likely to be cooperative
with protocol requirements, including attending all study visits.

Exclusion criteria:

1. The subject has a diagnosis of pulmonary arterial hypertension (PAH) or PH for reasons
other than COPD.

2. The subject has a confirmed diagnosis of WHO Group 3 PH, other than COPD.

3. The subject has received any FDA approved therapy including: prostacyclin therapy,
prostacyclin receptor agonist, endothelin receptor antagonist (ERA), phosphodiesterase
type 5 inhibitor (PDE5-I), or soluble guanylate cyclase (sGC) within 60 days of
Screening.

4. The subject has previously been diagnosed with alpha-1 antitrypsin deficiency.

5. The subject has shown intolerance to prostanoid therapy.

6. The subject is unable to tolerate low dose (3 breaths, 18 mcg) study drug and/or
unable to follow dosing regimen during the Screening Period.

7. The subject has evidence of clinically significant left-sided heart disease. Note:
Subjects with abnormal left ventricular function attributable entirely to impaired
left ventricular filling due to the effects of right ventricular overload will not be
excluded, but requires the Sponsor's approval.

8. The subject is receiving > 10 L/min of oxygen supplementation by any mode of delivery
at rest between the Screening Visit and Baseline Visit.

9. Current use of any inhaled tobacco/marijuana products.

10. Significant history of substance abuse within 6 months prior to start of Screening
Visit.

11. Exacerbation of COPD for active pulmonary or upper respiratory infection within 60
days prior to Screening Visit.

12. Initiation of pulmonary rehabilitation within 12 weeks prior to the Screening Visit 1.

13. The subject has an uncontrolled medical condition deemed by an Investigator to pose an
undue risk to the subject.

14. The subject has any form of congenital heart disease (repaired or unrepaired; other
than a patent foramen ovale).

15. The subject has a Body Mass Index ≥45 kg/m2 at Screening Visit 1.

16. The subject has any musculoskeletal disorder or has any other condition that would
limit ambulation.

17. Use of any investigational drug/device, or participation in any investigational study
with therapeutic intent within 30 days prior to Screening Visit 1.

18. Any other clinically significant illness or abnormal laboratory value(s) that might
adversely affect the interpretation of the study data.
We found this trial at
21
sites
Littleton, Colorado 80120
Principal Investigator: Ira Dauber, MD
Phone: 303-703-2124
?
mi
from
Littleton, CO
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
Principal Investigator: Robert Bourge, MD
Phone: 205-975-9964
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
Principal Investigator: Barbara LeVarge, MD
Phone: 984-974-2972
University of North Carolina at Chapel Hill Carolina’s vibrant people and programs attest to the...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
593 Eddy Street
Providence, Rhode Island 02903
401-444-4000
Principal Investigator: James Klinger, MD
Phone: 401-444-9097
Rhode Island Hospital Founded in 1863, Rhode Island Hospital in Providence, RI, is a private,...
?
mi
from
Providence, RI
Click here to add this to my saved trials
601 Elmwood Avenue
Rochester, New York 14642
(585) 275-2100
Principal Investigator: Daniel Lachant, DO
Univ of Rochester Medical Center One of the nation's top academic medical centers, the University...
?
mi
from
Rochester, NY
Click here to add this to my saved trials
47 New Scotland Ave
Albany, New York 12208
(518) 262-3125
Principal Investigator: Boris Medarov, MD
Phone: 518-262-1542
Albany Medical College Albany Medical Center is northeastern New York's only academic health sciences center...
?
mi
from
Albany, NY
Click here to add this to my saved trials
Atlanta, Georgia 30342
Principal Investigator: Paul Boyce, MD
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Aurora, Colorado 80045
Principal Investigator: Todd Bull, MD
Phone: 303-724-7466
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Austell, Georgia 30106
Principal Investigator: Amy Case, MD
Phone: 770-745-1404
?
mi
from
Austell, GA
Click here to add this to my saved trials
22 S Greene St
Baltimore, Maryland 21201
(410) 328-8667
Principal Investigator: Gautam Ramani, MD
Phone: 410-328-6885
University of Maryland Medical Center Founded in 1823 as the Baltimore Infirmary, the University of...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cincinnati, Ohio 45219
Principal Investigator: Peter Engel, MD
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Clearwater, Florida 33765
Principal Investigator: Francis Averill, MD
Phone: 727-210-4606
?
mi
from
Clearwater, FL
Click here to add this to my saved trials
2201 Inwood Rd
Dallas, Texas 75235
(214) 645-8300
Principal Investigator: Sonja Bartolome, MD
U.T. Southwestern Medical Center The story of UT Southwestern Medical Center is one of commitment...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Terry Fortin, MD
Phone: 919-668-1770
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Kissimmee, Florida 34741
Principal Investigator: Thomas O'Brien, MD
Phone: 407-624-4831
?
mi
from
Kissimmee, FL
Click here to add this to my saved trials
Louisville, Kentucky 40202
Principal Investigator: John McConnell, MD
Phone: 502-587-8000
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Madison, Wisconsin 53792
Principal Investigator: James Runo, MD
?
mi
from
Madison, WI
Click here to add this to my saved trials
1400 NW 12th Ave
Miami, Florida 33136
(305) 689-5511
Principal Investigator: David De La Zerda, MD
Phone: 305-243-9383
University of Miami Hospital The University of Miami changed the face of modern health care...
?
mi
from
Miami, FL
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
Principal Investigator: Michael Risbano, MD
Phone: 412-692-2210
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Santa Barbara, California 93102
Principal Investigator: Jeffrey Sager, MD
?
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Washington, District of Columbia 20010
Principal Investigator: Christopher Barnett, MD
Phone: 202-877-9328
?
mi
from
Washington,
Click here to add this to my saved trials